Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Biogen Idec has announced that the experimental ALS drug has not shown efficacy in a large-scale trial; its development will be discontinued
Posted on Thursday, January 3, 2013 - 02:41, By: Margaret Wahl
Biotechnology company Biogen Idec today announced disappointing results from its phase 3 trial of dexpramipexole, an experimental drug the company has been developing to treat amyotrophic lateral sclerosis (ALS).
The MDA-supported ALS Therapy Development Institute will collaborate with Biogen Idec and UCB to test CDP7657, a compound that modulates the immune system
Posted on Wednesday, December 21, 2011 - 17:04, By: Margaret Wahl
The ALS Therapy Development Institute (ALS TDI), an MDA-supported, nonprofit biotechnology organization dedicated to developing effective treatments for amyotrophic lateral sclerosis (ALS), will collaborate with two major biotechnology companies to investigate a potential treatment that modulates...
Biogen Idec is recruiting participants for its 'EMPOWER' trial, which will study the effects of the experimental treatment dexpramipexole in ALS
Posted on Thursday, March 31, 2011 - 05:30, By: Amy Madsen
Update 8/31/11: Enrollment screening for this study has closed to new prospective participants.
Posted on Tuesday, March 1, 2011 - 10:47, By: ALSN Staff
ALS TDI expansion among 2011 goals
Building on progress made in 2010, the MDA-supported ALS Therapy Development Institute (ALS TDI) has outlined a number of milestones it plans to meet in 2011.
Steve Perrin, ALS TDI chief scientific officer and CEO at the nonprofit biotech in Cambridge, Mass...